Clostridium Difficile Infection (CDI) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Clostridium difficile, a Gram-positive, anaerobic, spore-forming bacillus, exhibits a propensity to inhabit and propagate within the human gastrointestinal tract, particularly following colonic microbiota alterations after antibiotic administration. This microorganism is prevalent in various environments, such as water, air, human and animal feces, hospital surfaces, and soil. It thrives optimally at a temperature of approximately 37 degrees Celsius. The primary mode of transmission is fecal-oral. C. difficile produces two pivotal virulence factors: toxin A and toxin B. Although the majority of pathogenic strains associated with C. difficile infection generate both toxins, global reports indicate the existence of strains exclusively producing toxin B. Severe infections can lead to conditions like shock, ileus, and toxic megacolon. In developed nations, C. difficile is the leading cause of infectious diarrhea in hospitalized patients. Key primary risk factors encompass male gender, age exceeding 65 years, age below 1 year with comorbidities, extended hospital stays, and antimicrobial therapy. Secondary risk factors include comorbidities, inflammatory bowel diseases, immunodeficiency, HIV, malnutrition, low serum albumin levels, neoplastic diseases, cystic fibrosis, and diabetes. A significant proportion of C. difficile-infected patients, ranging from 20% to 35%, exhibit resistance to initial antibiotic treatment, with subsequent recurrence rates of 40–60%. Recurrent C. difficile infection imposes substantial morbidity, posing a significant burden on healthcare systems. Antibiotics represent the primary treatment for both primary and recurrent C. difficile infection (CDI), with a recent shift towards vancomycin and fidaxomicin over metronidazole. Recurrent infections afflict approximately 15-35% of CDI patients, often manifesting as a relapse rather than a reinfection with a new strain. Notably, subsequent recurrences are even more common after the initial relapse.
• The incidence of Clostridium difficile Infection (CDI) in the USA ranges from 0.8 million to 1 million cases and exhibits a higher prevalence among females.

Thelansis’s “Clostridium Difficile Infection (CDI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Clostridium Difficile Infection (CDI) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Clostridium Difficile Infection (CDI) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Clostridium Difficile Infection (CDI) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Clostridium Difficile Infection (CDI) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: Clostridium Difficile Infection (CDI), Clostridium Difficile Infection (CDI) market outlook, Clostridium Difficile Infection (CDI) competitive landscape, Clostridium Difficile Infection (CDI) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)